Enovis Corp.

As of October 10, 2025, Enovis Corp. is in a bearish trend with weak strength, indicated by negative signals from daily moving averages and Bollinger Bands, despite some mildly bullish signals from the weekly MACD and KST, and has underperformed the S&P 500 with a year-to-date return of -32.25%.

As of October 10, 2025, Enovis Corp. is in a bearish trend with weak strength, underperforming the S&P 500 significantly, with a year-to-date return of -32.34% compared to the S&P 500's 11.41%.

As of October 10, 2025, Enovis Corp. is in a bearish trend, indicated by bearish daily moving averages and Bollinger Bands, with a year-to-date return of -32.34% compared to the S&P 500's 11.41%.

As of August 22, 2025, Enovis Corp. shows a mildly bearish trend overall, with mixed technical signals across time frames, while outperforming the S&P 500 in the past week and month but underperforming year-to-date.

As of May 4, 2023, Enovis Corp. is considered overvalued and risky, with poor financial metrics such as a Price to Book Value of 0.69, an EV to EBITDA ratio of 12.95, and negative returns on capital and equity, while underperforming the market with a year-to-date return of -24.41%.

As of May 4, 2023, Enovis Corp. is considered overvalued with a risky valuation grade, reflected in its negative P/E ratio of -30.07, poor returns on capital, and a year-to-date return of -31.72%, significantly underperforming the S&P 500.

As of May 20, 2025, Enovis Corp. exhibits a bearish trend across multiple time frames, with strong bearish signals from MACD, Bollinger Bands, and moving averages, despite a mildly bullish KST signal.

As of March 2022, the management team of Enovis Corp. includes Chairman Mitchell Rales, CEO Matthew Trerotola, and several independent directors: Patrick Allender, Thomas Gayner, Rhonda Jordan, Liam Kelly, and A. Clayton Perfall. They oversee the company's strategic direction and operations.

Enovis Corp. is a technology company specializing in orthopedic care and fabrication technology products, operating in the small-cap industrial manufacturing sector. As of March 2025, it reported net sales of $559 million and a net loss of $56 million, with a market cap of approximately $1.76 billion.

As of Jun 18, Enovis Corp. has a market capitalization of 1,763.96 million and reported net sales of 2,150.19 million with a net profit of -811.16 million over the latest four quarters. Shareholder's funds are 2,562.26 million, and total assets amount to 4,718.78 million.